Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.
Eads JR, Krishnamurthi SS, Saltzman J, Bokar JA, Savvides P, Meropol NJ, Gibbons J, Koon H, Sharma N, Rogers L, Pink JJ, Xu Y, Beumer JH, Riendeau J, Fu P, Gerson SL, Dowlati A.
Eads JR, et al. Among authors: gerson sl.
Invest New Drugs. 2021 Feb;39(1):142-151. doi: 10.1007/s10637-020-00962-x. Epub 2020 Jun 17.
Invest New Drugs. 2021.
PMID: 32556884
Free PMC article.
Clinical Trial.